"I think that we need more companies making it, so we have enough drug for the people who need it and so that the price can be driven down so that people can afford it," Dr. Rochelle Walensky said.
July 6, 2020

On CNN's New Day, John Berman asked Dr. Rochelle Walensky, an infectious disease specialist at Massachusetts General, what she's hearing from colleagues in Texas about getting an adequate supply of remdesivir to treat coronavirus patients.

"I certainly am," she said.

"I see three problems with remdesivir right now. One is, a single manufacturer is making it, Gilead. Two, it is that we are going to run out. I think you can't look at the number of cases that are happening right now and not anticipate a shortage. And three, last week, it was priced at over $3,000 for a five-day course for a drug that we know costs $6 for a five-day course to make.

"So HHS has the power and the patent rights to this drug. I think we need generic competition. I think that we need more companies making it, so we have enough drug for the people who need it and so that the price can be driven down so that people can afford it."

Funny, isn't it? Trump doesn't care about what serves sick people. Quite consistently, he puts his thumb on the scale for Big Pharma.

Can you help us out?

For 17 years we have been exposing Washington lies and untangling media deceit, but now Facebook is drowning us in an ocean of right wing lies. Please give a one-time or recurring donation, or buy a year's subscription for an ad-free experience. Thank you.

Discussion

We are currently migrating to Disqus

On May 14, 2022, we started migrating our comments from Insticator back to Disqus. During this transition period, some posts will have Insticator and some Disqus. For more information on the transition, as well as information regarding old C&L accounts, please see this post.


We welcome relevant, respectful comments. Any comments that are sexist or in any other way deemed hateful by our staff will be deleted and constitute grounds for a ban from posting on the site. Please refer to our Terms of Service for information on our posting policy.